Related Experiment Video
Updated: Dec 27, 2025

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
Published on: October 25, 2024
Effects of chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT) on Th2/Th17-related immune modulation in an
Han-Na Go1, Seung-Hwa Lee1, Hyun-Ju Cho2
1Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea.
Abstract:
Exposure to chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT) has been associated with allergic contact dermatitis and occupational asthma. Despite this association however, no study has investigated the effects of CMIT/MIT exposure on the development of atopic dermatitis (AD). This study was conducted to investigate the influence of epicutaneous exposure to CMIT/MIT on AD in a mouse model and the underlying biological mechanisms. BALB/C mice were exposed to CMIT/MIT for 3 weeks and AD was developed using ovalbumin (OVA) epidermal sensitization. CMIT/MIT epicutaneous exposure in normal mice significantly enhanced AD-like phenotypes (e.g., transepidermal water loss, clinical score, total serum immunoglobulin E level and infiltration of inflammatory cells). In addition, CMIT/MIT exposure significantly augmented the mRNA expression level of T helper (Th) 2-related cytokines (thymic stromal lymphopoietin, interleukin (IL)-6 and IL-13), Th2 chemokine (chemokine (C-C motif) ligand 17) and the population of CD4+IL-4+ cells in the skin. Moreover, mice exposed to CMIT/MIT in the OVA challenge had greater AD-like phenotypes, higher IL-4 and IL-17A skin mRNA expression levels, and a larger population of CD4+IL-4+- and IL-17A+-producing cells in the skin-draining lymph nodes. Our current findings in a mouse model thus suggest that CMIT/MIT exposure may cause AD symptoms through the dysregulation of Th2/Th17-related immune responses.
Insights
Chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT) exposure worsens atopic dermatitis (AD) symptoms in mice. This occurs through the disruption of T-helper 2 (Th2) and T-helper 17 (Th17) immune responses, suggesting a link between CMIT/MIT and AD development.
Area of Science:
- Immunology
- Dermatology
- Toxicology
Background:
- Chloromethylisothiazolinone/methylisothiazolinone (CMIT/MIT) are preservatives linked to allergic contact dermatitis and occupational asthma.
- Previous research has not investigated the impact of CMIT/MIT exposure on the development of atopic dermatitis (AD).
- Understanding the role of environmental chemicals in AD pathogenesis is crucial for public health.
Purpose of the Study:
- To investigate the effects of epicutaneous CMIT/MIT exposure on AD development in a mouse model.
- To elucidate the underlying biological mechanisms contributing to CMIT/MIT-induced AD-like symptoms.
Main Methods:
- BALB/C mice were subjected to CMIT/MIT epicutaneous exposure for three weeks.
- Atopic dermatitis (AD) was induced using ovalbumin (OVA) epidermal sensitization.
- Analysis included assessment of AD-like phenotypes, serum immunoglobulin E levels, inflammatory cell infiltration, and gene/protein expression of cytokines and immune cells in skin and lymph nodes.
Main Results:
- CMIT/MIT exposure significantly exacerbated AD-like phenotypes, including increased transepidermal water loss, clinical scores, and inflammatory cell infiltration.
- Exposure elevated mRNA expression of T helper (Th) 2 cytokines (TSLP, IL-6, IL-13) and Th2 chemokine (CCL17), along with an increased population of CD4+IL-4+ cells in the skin.
- In OVA-challenged mice, CMIT/MIT exposure further augmented AD-like phenotypes and increased IL-4 and IL-17A mRNA expression and CD4+IL-4+- and IL-17A+-producing cells in skin-draining lymph nodes.
Conclusions:
- Epicutaneous exposure to CMIT/MIT can induce and worsen AD-like symptoms in a mouse model.
- CMIT/MIT exposure appears to dysregulate Th2 and Th17-related immune responses, contributing to AD pathogenesis.
- These findings suggest a potential role for CMIT/MIT in the development or exacerbation of atopic dermatitis.

